Cibc World Markets Lowered Tiffany & Co New (TIF) Holding By $2.28 Million; Edge Therapeutics, Inc. (EDGE) Covered By 4 Bulls

May 23, 2018 - By reb123z

Tiffany & Co. (NYSE:TIF) Logo

Among 4 analysts covering Edge Therapeutics (NASDAQ:EDGE), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Edge Therapeutics had 5 analyst reports since October 26, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Leerink Swann on Monday, October 26. The firm has “Outperform” rating given on Monday, October 26 by Credit Suisse. The firm earned “Market Outperform” rating on Monday, October 26 by JMP Securities. The company was initiated on Monday, October 26 by Guggenheim. Credit Suisse maintained Edge Therapeutics, Inc. (NASDAQ:EDGE) rating on Monday, May 9. Credit Suisse has “Outperform” rating and $18 target. See Edge Therapeutics, Inc. (NASDAQ:EDGE) latest ratings:

Cibc World Markets Inc decreased Tiffany & Co New (TIF) stake by 89.29% reported in 2017Q4 SEC filing. Cibc World Markets Inc sold 21,958 shares as Tiffany & Co New (TIF)’s stock declined 6.13%. The Cibc World Markets Inc holds 2,633 shares with $274,000 value, down from 24,591 last quarter. Tiffany & Co New now has $14.79B valuation. The stock increased 16.15% or $16.51 during the last trading session, reaching $118.75. About 3.32M shares traded or 104.04% up from the average. Tiffany & Co. (NYSE:TIF) has risen 1.55% since May 23, 2017 and is uptrending. It has underperformed by 10.00% the S&P500.

Cibc World Markets Inc increased Algonquin Pwr Utils Corp (AQUNF) stake by 284,648 shares to 1.94 million valued at $21.69 million in 2017Q4. It also upped Cenovus Energy Inc (NYSE:CVE) stake by 11.62M shares and now owns 12.04M shares. Kla (NASDAQ:KLAC) was raised too.

Among 29 analysts covering Tiffany & Co. (NYSE:TIF), 16 have Buy rating, 0 Sell and 13 Hold. Therefore 55% are positive. Tiffany & Co. had 91 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Tuesday, February 7 by HSBC. Jefferies maintained Tiffany & Co. (NYSE:TIF) rating on Tuesday, August 15. Jefferies has “Buy” rating and $110.0 target. The stock has “Buy” rating by Citigroup on Wednesday, October 7. The firm has “Outperform” rating given on Monday, March 20 by William Blair. On Tuesday, January 19 the stock rating was maintained by Mizuho with “Buy”. Jefferies maintained the stock with “Buy” rating in Thursday, September 28 report. Jefferies upgraded it to “Buy” rating and $100 target in Monday, December 21 report. Citigroup downgraded Tiffany & Co. (NYSE:TIF) on Tuesday, March 15 to “Neutral” rating. The firm has “Buy” rating by Monness Crespi & Hardt given on Friday, August 28. The company was maintained on Wednesday, January 17 by Wells Fargo.

More notable recent Tiffany & Co. (NYSE:TIF) news were published by: 247Wallst.com which released: “How Tiffany Blew Out Its Q1” on May 23, 2018, also Seekingalpha.com with their article: “Tiffany & Co: Overvalued Since 2018” published on May 22, 2018, Seekingalpha.com published: “Tiffany earnings preview” on May 22, 2018. More interesting news about Tiffany & Co. (NYSE:TIF) were released by: Streetinsider.com and their article: “Pre-Open Movers 05/23: (AVGR) (CARA) (TIF) Higher; (RRGB) (PFNX) (TCS) Lower (more…)” published on May 23, 2018 as well as Benzinga.com‘s news article titled: “Benzinga Pro’s 5 Stocks To Watch Today” with publication date: May 23, 2018.

Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital therapies for acute life-threatening neurological and other conditions. The company has market cap of $27.44 million. The Company’s lead product includes EG-1962, a polymer microsphere used for the treatment of aneurysmal subarachnoid hemorrhage. It currently has negative earnings. The firm is also developing EG-1964 for the management of chronic subdural hematoma as a prophylactic treatment to prevent recurrent bleeding on the surface of the brain.

Tiffany & Co. (NYSE:TIF) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>